CLINICAL AND LABORATORY CHARACTERISTICS AND OUTCOME OF COVID-19 PATIENTS ADMITTED TO THE ISOLATION WARD OF A PUBLIC SECTOR HOSPITAL
Article Sidebar
Main Article Content
Abstract
Objective: To evaluate the clinical and laboratory presentation and outcome of COVID-19 patients admitted to a public sector hospital in Pakistan.
Methodology: This is a retrospective, cross sectional chart review of COVID-19 patients admitted to Dr. Ruth K.M Pfau Civil Hospital Karachi Isolation Ward from 28th February till May 28th 2020.
Results: Out of 306 admitted patients, 216 (70%) tested SARS CoV-2 positive of whom median age was 45. COVID-19 was asymptomatic in 35 (16.2%), non-severe in 112 (51.9%), severe in 55 (25.5%) and critical in 14 (6.5%) patients. Severe/critical as compared to asymptomatic/non-severe disease was associated with co-morbidities (37 [53.6%] vs 35 [23.8%], p value <0.001), shortness of breath (50 [72.5%] vs 34 [23.1%], p value <0.001). Median [IQR] values demonstrated lower oxygen saturation (90 [87-92] vs 97 [97-98], p value <0.001) and lower absolute lymphocyte counts (1.3×109/L [0.9-1.82] vs 1.7×109/L [1.1-2.2], p value <0.001) with higher neutrophil to lymphocytic ratio (5.2 [3.3-8.4] vs 2.5 [1.6-3.7], p value <0.001), lactate dehydrogenase level (360U/L [271-566] vs 296U/L [207-377], p value <0.001), C-reactive protein (89mg/L [36-179] vs 19mg/L [0.9-91], p value <0.001) and ferritin level (580mg/L [331-1021] vs 341mg/L [163-679], p value <0.001). Of 216 patients, 2 (0.9%) died in the ward, whereas 13 (6%) were shifted to ICU of whom 12 died. Overall mortality was 14 (6.5%).
Conclusion: In COVID-19 patients admitted to a public sector hospital, severe disease was associated with co-morbidities and elevated inflammatory markers. Mortality was very high in those that required ICU care.
Article Details
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumo¬nia in Wuhan, China. Jama. 2020; 323(11):1061-9.
World health Organization (WHO). Covid-19 coronavirus-19 pandemic. Geneva: WHO; 2021.
Baqi S, Naz A, Sayeed MA, Khan S, Is¬mail H, Kumar V, et al. Clinical Charac¬teristics and Outcome of Patients With Severe COVID-19 Pneumonia at a Pub¬lic Sector Hospital in Karachi, Pakistan. Cureus. 2021; 13(2).
Asghar MS, Kazmi SJH, Khan NA, Akram M, Khan SA, Rasheed U, et al. Clinical profiles, characteristics, and outcomes of the first 100 admitted COVID-19 pa¬tients in Pakistan: A single-center retro¬spective study in a tertiary care hospital of Karachi. Cureus. 2020; 12(6).
Issued by Ministry of Health Services: Clinical Management Guidelines for COVID-19 Infections. GoPMoNHS; 2020 Dec. Report No.: 12-04.
Issued by Ministry of Health Services: Clinical Management Guidelines for COVID-19 Infections. GoPMoNHS; 2020 April. Report No.: 12-01.
Mazzucato M, Kattel R. COVID-19 and public-sector capacity. Oxford Review of Economic Policy. 2020; 36(S1):S256-S69.
Ayyaz M, Chima KK, Butt UI, Khan WH, Umar M, Farooka MW, et al. Combating COVID 19 in a public sector hospital in Pakistan. Ann Med Surg. 2020.
Rosenbaum L. The untold toll—the pandemic’s effects on patients without Covid-19. Mass Medical Soc. 2020.
Adibe B, Perticone K, Hebert C. Cre¬ating wellness in a pandemic: a prac¬tical framework for health systems responding to COVID-19. NEJM Catal Innov Care Deliv. 2020.
World health Organization (WHO). Men¬tal health and psychosocial consider¬ations during the COVID-19 outbreak. Geneva: WHO; 2020.
Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a sin¬gle-centered, retrospective, observa¬tional study. Lancet Resp Med. 2020; 8(5):475-81.
Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: a meta-analysis. Int J Infect Dis. 2020; 96:467-74.
Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary re¬sults from a multi-centre, randomized, controlled trial. MedRxiv. 2020.
Group TRC. Dexamethasone in hospi¬talized patients with Covid-19—prelim¬inary report. The N Eng J Med. 2020.
Furtado RH, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical tri¬al. Lancet. 2020; 396(10256):959-67.
Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clinical Mic Inf. 2020; 26(6):767-72.
Quah P, Li A, Phua J. Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature. Crit Care. 2020; 24:1-4.